Simultaneous Treatment with Azelnidipine and Olmesartan Inhibits Apoptosis of Hl-1 Cardiac Myocytes Expressing E334k cMyBPC

Abstract

Background:

Apoptosis appears to play an important role in the pathogenesis of hypertrophic cardiomyopathy (HCM). We have previously reported 3 HCM patients carrying the E334K MYBPC3, and that heterologous expression of E334K cMyBPC in cultured cells induced apoptosis. The purpose of this study was to identify pharmacological agents that would inhibit apoptosis in HL-1 cardiomyocytes expressing E334K cMyBPC.

Methods and Results:

E334K cMyBPC expression in cells increased levels of pro-apoptosis (p53, Bax and cytochrome c) and decreased levels of anti-apoptosis (Bcl-2 and Bcl-XL). While the beta blocker carvedilol (1 μM) normalized the level of p53 and Bcl-2 and the calcium channel blocker (CCB) bepridil (0.5 μM) normalized that of Bcl-2, both the CCB azelnidipine (1 μM) and the angiotensin receptor blocker (ARB) olmesartan (10 μM) normalized those of p53, Bax, cytochrome c, and Bcl-XL. Among those proteins, cytochrome c was the one which showed the highest degree of change. Both azelnidipine (0.1 μM) and olmesartan (1 μM) reduced the level of cytochrome c by 40.2±4.3% and 31.3±5.1%, respectively. The CCB amlodipine and the ARB valsartan reduced it only by 19.1±2.1% and 20.1±5.2%, respectively. Flow cytometric analysis and annexin V staining showed that treatment of cells with azelnidipine (0.1 μM) plus olmesartan (0.3 μM) or that with amlodipine (0.1 μM) plus valsartan (0.3 μM) reduced the number of apoptotic cells by 35.8±10.5% and 18.4±3.2%, respectively.

Conclusion:

Azelnidipine plus olmesartan or amlodipine plus valsartan inhibited apoptosis of HL-1 cells expressing E334K cMyBPC, and the former combination was more effective than the latter.

Key words

hypertrophic cardiomyopathy - mutant cardiac myosin binding protein C - calcium channel blocker - angiotensin receptor blocker - apoptosis

• References

• 1 Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001; 104: 557-567
• 2 Anselmi A, Gaudino M, Baldi A et al. Role of apoptosis in pressure-overload cardiomyopathy. J Cardiovasc Med 2008; 9: 227-232
• 3 Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2011; 124: e783-e831
• 4 Ni L, Zhou C, Duan Q et al. β-AR blockers suppresses ER stress in cardiac hypertrophy and heart failure. PLoS One 2011; 6: e27294
• 5 Lakshmanan AP, Thandavarayan RA, Palaniyandi SS et al. Modulation of AT-1R/CHOP-JNK-Caspase12 pathway by olmesartan treatment attenuates ER stress-induced renal apoptosis in streptozotocin-induced diabetic mice. Eur J Pharm Sci 2011; 44: 627-634
• 6 Kain V, Kumar S, Sitasawad SL. Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis. Cardiovasc Diabetol 2011; 10: 1-10
• 7 Bahrudin U, Morisaki H, Morisaki T et al. Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy. J Mol Biol 2008; 384: 896-907
• 8 Bahrudin U, Morikawa K, Takeuchi A et al. Impairment of ubiquitin-proteasome system by E334K cMyBPC modifies channel proteins, leading to electrophysiological dysfunction. J Mol Biol 2011; 4134: 857-878
• 9 White SM, Constantin PE, Claycomb WC. Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am J Physiol Heart Circ Physiol 2004; 286: H823-H829
• 10 Jinno T, Iwai M, Li Z et al. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004; 43: 263-269
• 11 Iwai M, Chen R, Ide A et al. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage. J Hypertens 2006; 24: 2023-2031
• 12 Ohyama T, Sato K, Kishimoto K et al. Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence. Br J Pharmacol 2012; 165: 1173-1187
• 13 Ohlstein EH, Douglas SA, Sung CP et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993; 90: 6189-6193
• 14 Willette RN, Aiyar N, Yue TL et al. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J Pharmacol Exp Ther 1999; 289: 48-53
• 15 Beaughard M, Ferrier M, Labrid C et al. Studies on the bradycardia induced by bepridil. Br J Pharmacol 1982; 75: 293-300
• 16 Ma J, Kishida S, Wang GQ et al. Comparative effects of azelnidipine and other Ca2+-channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells. J Cardiovasc Pharmacol 2006; 47: 314-321
• 17 Criscione L, de Gasparo M, Bühlmayer P et al. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 1993; 110: 761-771
• 18 Brunelle JK, Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 2009; 122: 437-441
• 19 Sawada T, Yamada H, Shiraishi J et al. Combination Effect of Calcium Channel Blocker and Valsartan on Cardiovascular Event Prevention in Patients with High-Risk Hypertension: Ancillary Results of the KYOTO HEART Study. Clin Exp Hypertens 2012; 34: 153-159
• 20 Okada K, Minamino T, Tsukamoto Y et al. Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation 2004; 110: 705-712
• 21 Tanaka T, Nangaku M, Miyata T et al. Blockade of calcium influx through L-type calcium channels attenuates mitochondrial injury and apoptosis in hypoxic renal tubular cells. J Am Soc Nephrol 2004; 15: 2320-2333
• 22 Yue TL, Ma XL, Wang X et al. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res 1998; 82: 166-174
• 23 Zeng H, Liu X, Zhao H. Effects of carvedilol on cardiomyocyte apoptosis and gene expression in vivo after ischemia-reperfusion in rats. J Huazhong Univ Sci Technolog Med Sci 2003; 23: 127-130
• 24 Schwarz ER, Kersting PH, Reffelmann T et al. Cardioprotection by Carvedilol: antiapoptosis is independent of beta-adrenoceptor blockage in the rat heart. J Cardiovasc Pharmacol Ther 2003; 8: 207-215
• 25 Chandar S, Yeo LS, Leimena C et al. Effects of mechanical stress and carvedilol in lamin A/C-deficient dilated cardiomyopathy. Circ Res 2010; 106: 573-582
• 26 Yamamoto E, Dong YF, Kataoka K et al. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension 2008; 52: 573-580
• 27 Sukumaran V, Watanabe K, Veeraveedu PT et al. Olmesartan, an AT1 antagonist, attenuates oxidative stress, endoplasmic reticulum stress and cardiac inflammatory mediators in rats with heart failure induced by experimental autoimmune myocarditis. Int J Biol Sci 2011; 7: 154-167
• 28 Fujimoto S, Satoh M, Horike H et al. Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production. Hypertens Res 2008; 31: 305-313
• 29 Yu G, Liang X, Xie X et al. Diverse effects of chronic treatment with losartan, fosinopril, and amlodipine on apoptosis, angiotensin II in the left ventricle of hypertensive rats. Int J Cardiol 2001; 81: 123-129
• 30 Ogino A, Takemura G, Kanamori H et al. Amlodipine inhibits granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction cardiac remodeling. Am J Physiol Heart Circ Physiol 2007; 293: H2271-H2280
• 31 Yamanaka S, Tatsumi T, Shiraishi J et al. Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. J Am Coll Cardiol 2003; 41: 870-878
• 32 Xiang Y, Huang J. Effect of valsartan and fosinopril on catecholamine-induced cardiac hypertrophy. Acta Pharmacol Sin 2000; 1: 850-854
• 33 Li W, Sun N, Liu W et al. Influence of valsartan on myocardial apoptosis in spontaneously hypertensive rats. Chin Med J 2002; 15: 364-366
• 34 Sawicki G, Jugdutt BI. Valsartan reverses post-translational modifications of the delta-subunit of ATP synthase during in vivo canine reperfused myocardial infarction. Proteomics 2007; 7: 2100-2110
• 35 Wu T, Dong Z, Geng J et al. Valsartan protects against ER stress-induced myocardial apoptosis via CHOP/Puma signaling pathway in streptozotocin-induced diabetic rats. Eur J Pharm Sci 2011; 42: 496-502
• 36 Tanifuji C, Suzuki Y, Geot WM et al. Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys. Kidney Blood Press Res 2009; 32: 239-249
• 37 Hosoya M, Ohashi J, Sawada A et al. Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice. Circ J 2010; 74: 798-806
• 38 Abe M, Maruyama N, Okada K et al. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertens Res 2011; 34: 935-941